MicroRNAs as theranostic markers in cardiac allograft
transplantation: from murine models to clinical practice

J 2021

MicroRNAs as theranostic markers in cardiac allograft transplantation: from murine models to clinical practice

NOVÁK, Jan, Táňa MACHÁČKOVÁ, Jan KREJČÍ, Julie DOBROVOLNÁ, Ondřej SLABÝ et. al.

Základní údaje

Originální název

MicroRNAs as theranostic markers in cardiac allograft transplantation: from murine models to clinical practice

Autoři

NOVÁK, Jan (203 Česká republika, domácí), Táňa MACHÁČKOVÁ (203 Česká republika, domácí), Jan KREJČÍ (203 Česká republika, domácí), Julie DOBROVOLNÁ (203 Česká republika, garant, domácí) a Ondřej SLABÝ (203 Česká republika, domácí)

Vydání

Theranostics, Lake Haven, Ivyspring International Publisher, 2021, 1838-7640

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30201 Cardiac and Cardiovascular systems

Stát vydavatele

Austrálie

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 11.600

Kód RIV

RIV/00216224:14110/21:00120135

Organizační jednotka

Lékařská fakulta

DOI

http://dx.doi.org/10.7150/thno.56327

UT WoS

000642591000004

Klíčová slova anglicky

microRNA; biomarker; cardiac allograft transplantation; acute cellular rejection; vasculopathy

Štítky

14110115, 14110116, 14110513, 14110518, podil, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 16. 5. 2022 09:00, Mgr. Tereza Miškechová

Anotace

V originále

Congestive heart failure affects about 23 million people worldwide, and cardiac allograft transplantation remains one of the last options for patients with terminal refractory heart failure. Besides the infectious or oncological complications, the prognosis of patients after heart transplantation is affected by acute cellular or antibody-mediated rejection and allograft vasculopathy development. Current monitoring of both conditions requires the performance of invasive procedures (endomyocardial biopsy sampling and coronary angiography or optical coherence tomography, respectively) that are costly, time-demanding, and non-comfortable for the patient. Within this narrative review, we focus on the potential pathophysiological and clinical roles of microRNAs (miRNAs, miRs) in the field of cardiac allograft transplantation. Firstly, we provide a general introduction about the status of cardiac allograft function monitoring and the discovery of miRNAs as post-transcriptional regulators of gene expression and clinically relevant biomarkers found in the extracellular fluid. After this general introduction, information from animal and human studies are summarized to underline the importance of miRNAs both in the pathophysiology of the rejection process, the possibility of its modulation by altering miRNAs levels, and last but not least, about the use of miRNAs in the clinical practice to diagnose or predict the rejection occurrence.

Návaznosti

EF15_003/0000469, projekt VaV

Název: Cetocoen Plus

EF17_043/0009632, projekt VaV

Název: CETOCOEN Excellence

MUNI/A/1403/2019, interní kód MU

Název: Diferenciální diagnostika a odhad prognózy interních nemocí 4 (Akronym: DIDIPRON 4)

Investor: Masarykova univerzita, Diferenciální diagnostika a odhad prognózy interních nemocí 4, DO R. 2020_Kategorie A - Specifický výzkum - Studentské výzkumné projekty

NV16-30537A, projekt VaV

Název: Cirkulující mikroRNA jako neinvazivní markery rejekce štěpu u pacientů po srdeční transplantaci

Přiložené soubory

1788739.pdf

Vyhledat podobné dokumenty

Citovat

NOVÁK, Jan, Táňa MACHÁČKOVÁ, Jan KREJČÍ, Julie DOBROVOLNÁ a Ondřej SLABÝ. MicroRNAs as theranostic markers in cardiac allograft transplantation: from murine models to clinical practice. Theranostics. Lake Haven: Ivyspring International Publisher, 2021, roč. 11, č. 12, s. 6058-6073. ISSN 1838-7640. Dostupné z: https://dx.doi.org/10.7150/thno.56327.

@article{1788739,
   author = {Novák, Jan and Macháčková, Táňa and Krejčí, Jan and Dobrovolná, Julie and Slabý, Ondřej},
   article_location = {Lake Haven},
   article_number = {12},
   doi = {http://dx.doi.org/10.7150/thno.56327},
   keywords = {microRNA; biomarker; cardiac allograft transplantation; acute cellular rejection; vasculopathy},
   language = {eng},
   issn = {1838-7640},
   journal = {Theranostics},
   title = {MicroRNAs as theranostic markers in cardiac allograft transplantation: from murine models to clinical practice},
   url = {https://www.thno.org/v11p6058.htm},
   volume = {11},
   year = {2021}
}

TY  - JOUR
ID  - 1788739
AU  - Novák, Jan - Macháčková, Táňa - Krejčí, Jan - Dobrovolná, Julie - Slabý, Ondřej
PY  - 2021
TI  - MicroRNAs as theranostic markers in cardiac allograft transplantation: from murine models to clinical practice
JF  - Theranostics
VL  - 11
IS  - 12
SP  - 6058-6073
EP  - 6058-6073
PB  - Ivyspring International Publisher
SN  - 18387640
KW  - microRNA
KW  - biomarker
KW  - cardiac allograft transplantation
KW  - acute cellular rejection
KW  - vasculopathy
UR  - https://www.thno.org/v11p6058.htm
N2  - Congestive heart failure affects about 23 million people worldwide, and cardiac allograft transplantation remains one of the last options for patients with terminal refractory heart failure. Besides the infectious or oncological complications, the prognosis of patients after heart transplantation is affected by acute cellular or antibody-mediated rejection and allograft vasculopathy development. Current monitoring of both conditions requires the performance of invasive procedures (endomyocardial biopsy sampling and coronary angiography or optical coherence tomography, respectively) that are costly, time-demanding, and non-comfortable for the patient. Within this narrative review, we focus on the potential pathophysiological and clinical roles of microRNAs (miRNAs, miRs) in the field of cardiac allograft transplantation. Firstly, we provide a general introduction about the status of cardiac allograft function monitoring and the discovery of miRNAs as post-transcriptional regulators of gene expression and clinically relevant biomarkers found in the extracellular fluid. After this general introduction, information from animal and human studies are summarized to underline the importance of miRNAs both in the pathophysiology of the rejection process, the possibility of its modulation by altering miRNAs levels, and last but not least, about the use of miRNAs in the clinical practice to diagnose or predict the rejection occurrence.
ER  -

NOVÁK, Jan, Táňa MACHÁČKOVÁ, Jan KREJČÍ, Julie DOBROVOLNÁ a Ondřej SLABÝ. MicroRNAs as theranostic markers in cardiac allograft transplantation: from murine models to clinical practice. \textit{Theranostics}. Lake Haven: Ivyspring International Publisher, 2021, roč.~11, č.~12, s.~6058-6073. ISSN~1838-7640. Dostupné z: https://dx.doi.org/10.7150/thno.56327.

Podrobný výpis o publikaci